Urticaria
- May 2022
- 20min
Therapeutic classes inducing this adverse event
Antiangiogenic agent, BRAF inhibitor, CTLA4 inhibitor, Chemotherapy, Cyclin-dependent kinase 4/6 inhibitor, EGFR inhibitor, Hormone therapy, KIT inhibitor, MEK inhibitor, PD-1 inhibitor, RAF inhibitor, Radiotherapy, SMO inhibitor, mTOR inhibitor
CTCAE V5.0
Urticarial lesions covering <10% bsa;topical intervention indicated
For this toxicity, our classification differs from the CTCAE
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Urticarial lesions covering 10 - 30% BSA; oral intervention indicated
SIMPLIFIED GRADING
Isolated cutaneous urticaria
For this toxicity, our classification differs from the CTCAE
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
CTCAE V5.0
Urticarial lesions covering >30% BSA; IV intervention indicated
SIMPLIFIED GRADING
Urticaria associated with signs of severity: angioedema without pharyngo-laryngeal involvement, hypotension, malaise or bronchospasm
IV intervention indicated
For this toxicity, our classification differs from the CTCAE
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
SIMPLIFIED GRADING
Anaphylactic shock
Laryngeal edema
Life-threatening consequences
For this toxicity, our classification differs from the CTCAE
References
Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer. 2018;26:2871-7.
Browse for more adverse events